2420: Poolbeg Pharma - POLB 001 Trial Activated as CRS Prevention Study Moves Into Patients
About this episode
Poolbeg Pharma activates the first clinical trial site for its POLB 001 study aimed at preventing Cytokine Release Syndrome in cancer patients.
Poolbeg Pharma has announced the activation of the first clinical trial site for its POLB 001 TOPICAL study, marking a key operational milestone for its lead programme. The trial will evaluate POLB 001 as a potential preventative treatment for Cytokine Release Syndrome in relapsed/refractory multiple myeloma patients receiving teclistamab, an approved bispecific antibody. With recruitment now underway and interim data expected in summer 2026, the study could provide an important early readout on POLB 001’s role in improving the safety and accessibility of cancer immunotherapies.
More episodes of The Vox Markets Podcast
- 2421: 2 P’s on a Pod: Small Cap Investing with Paul Hill & Paul Scott
- 2419: Finseta Interview - Last week’s positive FY’25 results and ‘in line’ outlook
- 2418: ECR fine-tunes gold production process at Raglan
- 2417: Mindflair benefits as a key investment, CameraMatics secures €48m growth investment
- 2416: Will Great Western Mining's OTC listing boost liquidity?
- 2415: Pinnacle Silver & Gold: Gold recoveries better than 97% at El Potrero
Explore listener stats, chart rankings, contacts and more on the The Vox Markets Podcast podcast page.